ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
26.52
-0.39
(-1.45%)
Closed 02 February 8:00AM
26.54
0.02
(0.08%)
After Hours: 11:58AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
26.54
Bid
-
Offer
-
Volume
37,338,153
26.42 Day's Range 27.01
24.48 52 Week Range 31.54
Market Cap
Previous Close
26.91
Open
26.92
Last Trade
1
@
26.55
Last Trade Time
Financial Volume
US$ 998,622,642
VWAP
26.7454
Average Volume (3m)
43,008,646
Shares Outstanding
5,666,990,035
Dividend Yield
6.48%
PE Ratio
70.93
Earnings Per Share (EPS)
0.37
Revenue
58.5B
Net Profit
2.12B

About Pfizer Inc

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers includ... Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 vaccine sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
New York, New York, USA
Founded
-
Pfizer Inc is listed in the Pharmaceutical Preparations sector of the New York Stock Exchange with ticker PFE. The last closing price for Pfizer was US$26.91. Over the last year, Pfizer shares have traded in a share price range of US$ 24.48 to US$ 31.54.

Pfizer currently has 5,666,990,035 shares in issue. The market capitalisation of Pfizer is US$152.50 billion. Pfizer has a price to earnings ratio (PE ratio) of 70.93.

Pfizer (PFE) Options Flow Summary

Overall Flow

Bullish

Net Premium

695k

Calls / Puts

209.09%

Buys / Sells

166.67%

OTM / ITM

47.83%

Sweeps Ratio

0.00%

PFE Latest News

Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS...

Pfizer’s BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer

Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with...

Pfizer’s Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

Clinically meaningful and statistically significant results are the first pivotal Phase 3 data for sasanlimab, a subcutaneously administered PD-1 inhibitor If approved, sasanlimab would be the...

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 43rd Annual J.P...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.521.9984627209826.0227.0725.963801360926.67393902CS
4-0.12-0.45011252813226.6627.5725.963568961226.61423227CS
12-0.54-1.994091580527.0827.5724.484300864626.03469963CS
26-4.69-15.017611271231.2331.3224.483681012527.47279724CS
52-0.62-2.2827687776127.1631.5424.483811332027.60768399CS
156-27.3-50.70579494853.8456.3224.483032924335.31064961CS
260-10.41-28.173207036536.9561.7124.483146865437.5627241CS

PFE - Frequently Asked Questions (FAQ)

What is the current Pfizer share price?
The current share price of Pfizer is US$ 26.54
How many Pfizer shares are in issue?
Pfizer has 5,666,990,035 shares in issue
What is the market cap of Pfizer?
The market capitalisation of Pfizer is USD 152.5B
What is the 1 year trading range for Pfizer share price?
Pfizer has traded in the range of US$ 24.48 to US$ 31.54 during the past year
What is the PE ratio of Pfizer?
The price to earnings ratio of Pfizer is 70.93
What is the cash to sales ratio of Pfizer?
The cash to sales ratio of Pfizer is 2.57
What is the reporting currency for Pfizer?
Pfizer reports financial results in USD
What is the latest annual turnover for Pfizer?
The latest annual turnover of Pfizer is USD 58.5B
What is the latest annual profit for Pfizer?
The latest annual profit of Pfizer is USD 2.12B
What is the registered address of Pfizer?
The registered address for Pfizer is 235 EAST 42ND STREET, NEW YORK, NEW YORK, 10017
What is the Pfizer website address?
The website address for Pfizer is www.pfizer.com
Which industry sector does Pfizer operate in?
Pfizer operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MBIMBIA Inc
US$ 7.11
(15.42%)
2.37M
ALURAllurion Technologies Inc
US$ 6.07
(13.46%)
571.74k
SESSES AI Corporation
US$ 1.19
(13.33%)
24.78M
ENFYEnlightify Inc
US$ 1.36
(12.40%)
95.69k
LITBLightInTheBox Holding Co Ltd
US$ 1.155
(12.14%)
17.51k
DECKDeckers Outdoor
US$ 177.46
(-20.46%)
15.04M
BZHBeazer Homes USA Inc New
US$ 22.18
(-19.93%)
2.11M
VSTSVestis Corporation
US$ 14.00
(-11.62%)
6.16M
KOREKORE Group Holdings Inc
US$ 2.29
(-9.13%)
36.39k
NOVASunnova Energy International Inc
US$ 2.565
(-9.04%)
14.63M
FFord Motor Company
US$ 10.08
(-0.79%)
103.99M
QBTSD Wave Quantum Inc
US$ 5.94
(5.32%)
75.07M
BBDBanco Bradesco SA
US$ 2.12
(0.47%)
55.89M
NUNu Holdings Ltd
US$ 13.25
(-1.41%)
48.21M
VZVerizon Communications Inc
US$ 39.39
(-0.20%)
45.19M

PFE Discussion

View Posts
Vexari Vexari 5 hours ago
73.9% post covid vax deaths found directly linked

To vaccination on autopsy

data reported from the largest autopsy survey

phillip.altman
Nov 19, 2024
👍️0
axelvento axelvento 2 days ago
Scientists estimate that the COVID vaccine saved 3 million lives and prevented 18 million hospitalizations.

President Trump called it "one of the greatest miracles of the ages."

RFK Jr. asked the FDA to revoke the emergency use of vaccines.

$MRNA
$PFE

https://x.com/SenSanders/status/1884991168460534022?ref_src=twsrc%5Etfw%7Ctwcamp%5Etweetembed%7Ctwterm%5E1884991168460534022%7Ctwgr%5E41efa3783bf583914279bce85e9325050c2fc862%7Ctwcon%5Es1_&ref_url=https%3A%2F%2Fwww.thedailybeast.com%2Fbernie-sanders-corners-robert-f-kennedy-jr-did-covid-vaccine-save-lives%2F

https://www.thedailybeast.com/bernie-sanders-corners-robert-f-kennedy-jr-did-covid-vaccine-save-lives/
👍️ 1 💯 2 😀 1
Monroe1 Monroe1 2 days ago
But newbies look as well, Moderna's killer jab is worse than fuzzy Pfizers. What's going on here?
I expect Pfizer will hit Moderna hard with this info... or not? Why not?
https://kirschsubstack.com/p/breaking-official-czech-record-level?publication_id=548354&post_id=156125860&isFreemail=true&r=x7hm&triedRedirect=true


Now you know part of the real story. Who is protecting who?
👍️ 1 🗑️ 1
Monroe1 Monroe1 3 days ago
These are turbulent times and to be wary and cautious may not be a bad idea.
https://dailynewscycle.com/pfizer-to-pay-60m-in-false-claims-settlement-for-drug-kickbacks-doj-announces/
For any newbies, Pfizer has not a great reputation.
😎 1
axelvento axelvento 4 days ago
trading just under 9 times forward earnings estimates right now$$$$$$$$
👍️ 2 💪 2 💰️ 2
axelvento axelvento 4 days ago
Pfizer avoids board nominations from Starboard as proxy fight rolls on

https://www.fiercepharma.com/pharma/pfizers-board-left-untouched-annual-meeting-proxy-fight-starboard-rolls-bloomberg
💯 1 🔝 1
axelvento axelvento 4 days ago
Trump HHS secretary nominee RFK Jr to stress he's not 'anti-vaccine' at confirmation hearing
And in his opening statement at his confirmation hearing, Kennedy will spotlight that "all of my kids are vaccinated, and I believe vaccines have a critical role in healthcare."

https://www.foxnews.com/politics/scoop-trump-health-secretary-nominee-rfk-jr-stress-confirmation-hearing-hes-not-anti-vaccine
💯 1 🔝 1
axelvento axelvento 4 days ago
PFE will report its fourth-quarter and full-year 2024 earnings on Feb. 4, before market open.
👆️ 2 👍️ 2 😀 1
Monroe1 Monroe1 4 days ago
It's all about right and wrong. It is coming down to that. PFE will pay the piper.

New era has emerged. Let's see how all this plays out. The past has a way of catching up if overlooked.

Pfizer would be smart to somehow make amends for past mistakes in regards to mRna and continue on their
path to cutting out on unneeded collaborations. My price target for re-entering on the long side is $22-24 for
purposes of flipping only. I always hold back a few shares just in case. New personnel at the FDA is not going
to make things easier as we enter into the new year.
👍️0
Monroe1 Monroe1 4 days ago
https://www.benzinga.com/insights/analyst-ratings/25/01/43281053/pfizer-stock-a-deep-dive-into-analyst-perspectives-6-ratings
Where it goes nobody knows.
👍️0
axelvento axelvento 5 days ago
Pfizer to Showcase Advancements Across Genitourinary Cancers at ASCO GU Cancers Symposium


https://www.pfizer.com/news/press-release/press-release-detail/pfizer-showcase-advancements-across-genitourinary-cancers?cid=tw_pbg_onco_asco-gu-2025_0125&ttype=tw&linkId=729229623
👍️ 1 🔝 1 🤙 1
axelvento axelvento 6 days ago
News https://www.businesswire.com/news/home/20250124736884/en/Pfizer%E2%80%99s-BRAFTOVI%C2%AE-Combination-Regimen-Demonstrates-Improved-Response-in-Patients-with-BRAF-V600E-Mutant-Metastatic-Colorectal-Cancer
👆️ 1 💯 1
MomsSpaghetti MomsSpaghetti 7 days ago
I anticipate a deal getting struck with someone just prior to or at 12 week top line data read out. I have seen many cases where acquisition occurs prior to FDA approval. Arena Pharmaceuticals (Acquired by Pfizer in 2022) - Arena had a strong focus on immune-inflammatory and CNS-related disorders. Etrasimod, a drug for immune-inflammatory diseases, was a key focus, though Pfizer valued the potential across multiple therapeutic areas. Acquisition Price: $6.7 billion.

Going to be interesting.
👍️0
north40000 north40000 1 week ago
Good idea, moms. We have both MNMD and PFE in our portfolios. PFE's expensive acquisition of SGEN(very profitable for us) has been slow to bring enough revenue to the balance sheet to solve PFE's problem being termed a laggard in pharma-land. HLS in Canada terminated a contract with PFE that involved its marketing of AMRN's Vascepa to Canadian GPs, a contract that I had hoped would evolve into PFE acquiring our 225k shares of AMRN by now. PFE CEO Bourla was at DAVOS this past week. We should see whether any deals were struck shortly, I think.
👆️ 1 💯 1
Vexari Vexari 1 week ago
Time will tell
So I ask you. Would you be curious to know .....
A whole lot of so called professionals need to go to jail... or worse.
https://kirschsubstack.com/p/breaking-ican-acquires-critical-fda?publication_id=548354&post_id=155479991&isFreemail=true&r=x7hm&triedRedirect=true Certain protective laws

Were reversed

Immunity

Being one

Accountably

Coming to a theater

Near you
🎃 1 👎️ 1 💊 1 🗑️ 1 🤪 1
Monroe1 Monroe1 2 weeks ago
they need to do something good to turn the ship around. the company can certainly look forward to more scrutiny now that there is a new sheriff in town.
👍️0
DewDiligence DewDiligence 2 weeks ago
PFE raises $3.1B cash by paring HLN stake (as reported yesterday by Bloomberg). After the sale PFE’s HLN stake is reduced from 15% to 7.3%, which means that PFE has another (roughly) $3B source of capital whenever it wants.
👆️ 1 👍 1 💯 1
Monroe1 Monroe1 3 weeks ago
This is a long way from where it once was. Yet the company is hemorrhaging. Still they up the dividend to slow the bleeding.
This is a long way from over. The biggest scam in world history just won't go away.
https://givemefive.news/dod-ignored-herd-immunity-data-before-vaccine-mandate/
👍️0
axelvento axelvento 3 weeks ago
has announced that it will be paying its dividend of $0.43 on the 7th of March, an increased payment from last year's comparable dividend. This makes the dividend yield 6.5%, which is above the industry average

$PFE
👆️ 1 👍 1 😀 1
axelvento axelvento 3 weeks ago
so it seems
👍️0
Monroe1 Monroe1 3 weeks ago
is that in competition with Keytruda?
👍️0
Vexari Vexari 3 weeks ago
FDA Mandates Nerve Damage Warnings for 2 RSV Vaccines

Respiratory syncytial virus (RSV) activity is currently deemed to be ‘very high’ in many parts of the United States, according to CDC.

By Naveen Athrappully
1/9/2025 Updated: 1/10/2025

The U.S. Food and Drug Administration (FDA) ordered two respiratory syncytial virus (RSV) vaccine manufacturers to include a potentially paralytic side effect warning related to nerve damage on product labels.

The manufacturers, GSK and Pfizer, manufacturing Arexvy and Abrysvo vaccines respectively, must now include a warning stating a risk of Guillain-Barre syndrome (GBS) following vaccination, according to a Jan. 7 statement from the agency.

GBS is a rare disorder in which the immune system ends up damaging nerve cells, which leads to weakness in the muscles and potential near-total paralysis, depending on severity.

RSV is a common respiratory virus that infects the throat, nose, and lungs, and typically spreads during fall and winter seasons. Infected people can experience symptoms similar to that of a common cold such as a runny nose, congestion, sneezing, and coughing.

The FDA said the following statement is to be included in the Warnings and Precautions section of the two vaccines: “The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with Abrysvo” or with “Arexvy” for that vaccine.

Arexvy is used by people aged 50 and older to deal with lower respiratory tract disease caused by RSV, while Abrysvo has been approved for use in adults aged 18 and above.

The labeling requirement follows an observational study conducted by the FDA.

In the study, the agency found there was an “increased risk of GBS during the 42 days following vaccination, with an estimated 9 excess cases of GBS per million doses of Abrysvo, and an estimated 7 excess cases of GBS per million doses of Arexvy administered to individuals 65 years of age and older.”

However, despite these results, the FDA determined that “the benefits of vaccination with Abrysvo and Arexvy continue to outweigh their risks.”

According to the U.S. Centers for Disease Control and Prevention (CDC), early symptoms of GBS can include feelings of weakness and tingling.

“People with GBS usually first feel these symptoms in both legs. Then, they might feel these symptoms in their arms and upper body,” it said. “Symptoms can progress over hours, days, or weeks.” The weakness keeps increasing until people are unable to use certain muscles.

“People with GBS need to be hospitalized,” the agency said. “Most people start to recover 2–3 weeks after symptoms start. Recovery may take as little as a few weeks or as long as a few years. Most people recover fully, but some have permanent nerve damage. Some people have died from GBS.”

The Epoch Times reached out to GSK and Pfizer for comment.


RSV Vaccine Usage and Risks

The RSV vaccine label update comes as the overall respiratory illness activity in the United States is deemed to be at a “high” level, with RSV activity being “very high in many areas of the country, particularly in young children,” according to the CDC.

“Emergency department visits and hospitalizations are highest in children and hospitalizations are elevated among older adults in some areas.”

The agency recommends all babies be protected from RSV by either vaccinating mothers or by giving an antibody to the infant.

Even if the mother is not at high risk for severe RSV, the vaccination is important since the pregnant woman will “pass the protection” to her baby, the CDC said. “It takes two weeks to develop protection (antibodies) and for protection to pass on to your baby.”

This protection lasts for the first six months of the infant’s life “while they are at highest risk of severe RSV.”

Pregnant women who have already taken an RSV vaccine during a previous pregnancy are not recommended to take it again. Instead, the baby should get nirsevimab, an antibody.

CDC recommends antibodies to “all babies younger than eight months of age born to mothers who did not receive a maternal RSV vaccine (Pfizer’s Abrysvo) during pregnancy.”

For older adults, the CDC advises vaccination for 60 to 74-year-olds who are at increased risk of severe RSV and for all individuals aged 75 and above.

However, the agency warns that vaccination could result in certain adverse events. “Side effects such as pain, redness, and swelling where the shot is given, fatigue, fever, headache, nausea, diarrhea, and muscle or joint pain may occur after you get an RSV vaccine.”

“These side effects are usually mild. Patients who have experienced these symptoms when getting other vaccines might be more likely to experience them after getting an RSV vaccine,” it said.

Epoch Times
Subscription necessary to read on site
🎃 1 💊 1 🗑️ 1 🤪 1
axelvento axelvento 3 weeks ago
if approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
👆️ 1 👍️ 1
Monroe1 Monroe1 3 weeks ago
More phuzzy phyzer prhoblems https://www.theepochtimes.com/health/fda-mandates-nerve-damage-warnings-for-2-rsv-vaccines-5789027?src_src=healthnoe&src_cmp=health-2025-01-10&est=AAAAAAAAAAAAAAAAdbAmeh0exsTo9bIGsWoXCLt3DMv%2BeZd%2FEugtIdyHPONOLA%3D%3D
👍️ 1
Vexari Vexari 3 weeks ago
Create a problem

Time reaction

Solve problem

Media controls

The agenda

Who controls

The media

Getting

Close
💊 1 🗑️ 1 🚽 1 🤪 1
axelvento axelvento 3 weeks ago
Pfizer’s Subcutaneous PD-1 Blocker Aces Phase III in Bladder Cancer, Carves Niche Versus Keytruda

https://www.biospace.com/drug-development/pfizers-subcutaneous-pd-1-blocker-aces-phase-iii-in-bladder-cancer-carves-niche-versus-keytruda
👍 1 💪 2 💯 2
biotech_researcher biotech_researcher 3 weeks ago
$PFE One good bullish news. 

Pfizer (PFE) announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antibody, in combination with Bacillus Calmette-Guerin as induction therapy with or without maintenance in patients with BCG-naive, high-risk non-muscle invasive bladder cancer.

In terms of bladder cancer, market size is almost 4b in 2023. This is growing and expected to be  5.5b.

At least few dollar worth asset for the stock. 
Thank you very much for the hard work PFE.
👆️ 1 👍️ 1 💪 1
Vexari Vexari 3 weeks ago
Why did Pfizer stop testing on animals

What about human testing
🕳️ 1 🗑️ 1 🫵 1
Vexari Vexari 4 weeks ago
What are the ingredients?

In the next round

Of vaccines
👎️ 1 💊 1 🕳️ 1 🗑️ 1 🤪 1
biotech_researcher biotech_researcher 4 weeks ago
Vexari, any questions???
👍️0
biotech_researcher biotech_researcher 4 weeks ago
PFE on fire! Market sees right through the nonsense...  ST target: $30
👍️ 2 💯 1
Monroe1 Monroe1 4 weeks ago
keep digging mister propaganda: https://petermcculloughmd.substack.com/p/new-study-covid-19-mrna-injections?publication_id=1119676&post_id=154280211&isFreemail=true&r=x7hm&triedRedirect=true

Cleveland Clinic
👍️0
biotech_researcher biotech_researcher 4 weeks ago
Nope...
👍️0
biotech_researcher biotech_researcher 4 weeks ago
Nope....
👍️0
Vexari Vexari 4 weeks ago
Interesting

To say the least

Dive bomber

In and out
🎃 1 👎️ 1 💊 1 🗑️ 1 🤪 1
Monroe1 Monroe1 4 weeks ago
https://www.statista.com/statistics/1318652/covid-vaccine-lawsuits-industry/
👍️0
Monroe1 Monroe1 4 weeks ago
yes, it will get better after bankruptcy. I plan on buying in at that time or instruct my grand kids to do so.
👍️0
Monroe1 Monroe1 4 weeks ago
why no answer? perhaps mr. biotick works for pfizzer.
👍️0
Monroe1 Monroe1 4 weeks ago
How many people get it? The spike protein stays in the body and continues to do damage as you age.
Do investors think this is going away any time soon especially now that some real honest folks are about
to run the show? Tik Tok
https://petermcculloughmd.substack.com/p/catastrophic-neurological-and-psychiatric?publication_id=1119676&post_id=154201714&isFreemail=true&r=x7hm&triedRedirect=true
👍️0
Vexari Vexari 1 month ago
Why would that be?
Complete horse hockey..
👍️ 1 💨 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
biotech_researcher biotech_researcher 1 month ago
Complete horse hockey..
👍️ 1 💥 1 💯 1
Vexari Vexari 1 month ago
The bird

Is a metamorphical germ

Eating

Dead cell debris
👎️ 1 🕳️ 1 🗑️ 1 🚽 1 🤪 1
Vexari Vexari 1 month ago
Can not catch something that doesn't exist

Facts don't lie

Open to board discussion
👎️ 1 🗑️ 1 🤥 1 🤪 1 🫵 1
Monroe1 Monroe1 1 month ago
Yep, otherwise they would not be cutting out even some of the most promising collaborations. They are going to have scrap others too in order to stave off bankruptcy possibility in the near future with the pending and growing lawsuits. Other surprises may be waiting too in the form of new and real scrutiny by RFKjr
and the new FDA commissioner. Things are looking ugly and Pfizer is going to pay the consequences for cheating the system, withholding data, and corrupt political collaborations. Not good Pfizer. Looking for investor lawsuits to gain strength.
https://www.businesswire.com/news/home/20241230895593/en/Sangamo-Therapeutics-to-Regain-Full-Rights-to-Hemophilia-A-Gene-Therapy-Program-Following-Pfizer%E2%80%99s-Decision-to-Cease-Development-of-Giroctocogene-Fitelparvovec
👍️0
IHuser IHuser 1 month ago
imo...

Wikipedia • Coronavirus disease 2019 is a contagious disease caused by the coronavirus SARS-CoV-2. The disease spread worldwide, resulting in the COVID-19 pandemic.
The symptoms of COVID-19 can vary but often include fever, fatigue, cough, breathing difficulties, loss of smell, and loss of taste.

Like a snake bit me...... PFE



PFE


(shivering)


IHuser
👍️0
Saving Grace Saving Grace 1 month ago
Yup, this horseshit is being pumped by Wall Street crooks, cooking the books. It's over for big pharma.

Eli Lilly and Company & Pfizer Inc. are a disaster in the making.

👍️0
Vexari Vexari 1 month ago
When financial guidance

Is based on a lie

Where does one go

From there
👎️ 1 🕳️ 1 🗑️ 1 🚽 2 🤪 1
Vexari Vexari 1 month ago
They knew what they were doing

Nothing can stop

What is coming
🎃 1 👎️ 2 💊 1 🗑️ 1 🧻 1
IHuser IHuser 1 month ago
imo...you are postulating and swaying perception without addressing the science or patents for insured improved health... yea that's because.. I have the market on my side....especially the women now.....and this pos is a done issue stick a fork in it and go play in traffic.....-look at the share price now blue boy ~


PFE





IHuse4
👍️0
IHuser IHuser 1 month ago
imo...you are very provacative and could wind up bankrupting this entire scam...and should be mindful of the implications...PFE


OK~ go fuck off




PFE



IHuser
👍️0

Your Recent History

Delayed Upgrade Clock